TREM2 Agonist Therapy for ABCD1-Deficient Microglial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no known treatments for diseases and disorders caused by ATP-binding cassette transporter 1 (ABCD1) dysfunction, such as X-linked adrenoleukodystrophy (X-ALD), which leads to neurological and adrenal gland diseases due to microglial dysfunction and VLCFA accumulation.
Innovation Solution
Administering a compound that acts as a TREM2 agonist to increase the activity of triggering receptor expressed on myeloid cells 2 (TREM2) to rescue microglia function in patients with ABCD1 mutations, thereby preventing microglial apoptosis and maintaining an anti-inflammatory environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ABCD1 function is lost, then microglial peroxisomal transport is impaired, but this leads to VLCFA accumulation and microglial dysfunction
Solution Approach 1:
The patent introduces TREM2 as an intermediary receptor that mediates the protective effect against ABCD1 deficiency. By activating TREM2 through its ligands (such as CSF1R ligands), the system creates a compensatory signaling pathway that protects microglia from VLCFA accumulation effects, thereby maintaining microglial function without directly addressing the ABCD1 defect
Solution Approach 2:
The patent changes the functional state of TREM2 from its baseline state to an activated state through ligand binding. This parameter change in TREM2 activation status triggers downstream signaling cascades (including PI3K/Akt and MAPK pathways) that confer protection against microglial death and dysfunction, effectively altering the cellular response to ABCD1 deficiency
2Reliability
If no treatment exists for ABCD1 dysfunction, then patients can only manage symptoms, but this leaves the underlying disease progression untreated
Solution Approach 1:
The patent identifies TREM2 as a therapeutic intermediary target that can be modulated to provide disease-modifying treatment. By using TREM2 ligands (such as CSF1R ligands) as mediators, the invention enables treatment of ABCD1-related diseases through mechanisms that do not require direct correction of the ABCD1 defect, thereby improving treatment efficacy while maintaining feasibility
Solution Approach 2:
The patent positions TREM2 as a universal therapeutic target that can address multiple aspects of ABCD1-related pathology. The TREM2 activation pathway provides broad protection against microglial dysfunction, demyelination, and neurodegeneration, making it a multi-functional treatment approach that covers various disease manifestations
3Reliability
If microglia are activated to compensate for ABCD1 deficiency, then microglial proliferation and chemotaxis increase, but this may lead to increased astrocytosis
Solution Approach 1:
The patent implies a feedback mechanism where TREM2 activation provides protective signals that balance the proliferative and chemotactic effects of microglial activation. The downstream signaling pathways (PI3K/Akt, MAPK) regulate microglial behavior in a coordinated manner, suggesting that the activation process includes feedback control to prevent excessive astrocytosis while maintaining beneficial microglial responses
Data Source
AI summary
The present invention provides a method of treating a disease or disorder caused by and/or associated with ABCD1 dysfunction in a human patient, the method comprising administering to the patient in need thereof an effective amount of a compound that increases the activity of triggering receptor expressed on myeloid cells 2 (TREM2). In some embodiments, compound that increases the activity of TREM2 is an agonist of TREM2. In some embodiments, the agonist of TREM2 is a small molecule agonist of TREM2 or an antibody agonist of TREM2.